Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2019

01-08-2019 | Bacterial Peritonitis | Original Article

Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis

Authors: Eric Ardolino, Susan S. Wang, Vilas R. Patwardhan

Published in: Digestive Diseases and Sciences | Issue 8/2019

Login to get access

Abstract

Objectives

There are few studies addressing the impact of cephalosporin and quinolone resistance on hospital length of stay and mortality in spontaneous bacterial peritonitis (SBP). We aim to describe the shifting epidemiology of SBP at our institution and its impact on clinical outcomes.

Methods

We performed a single-center retrospective cohort study of all cases of SBP from 2005 to 2015 at a transplant center. Cases were identified using hospital billing data. Patient data were confirmed using the electronic medical record. Univariate and multivariate logistic regression and Cox proportional hazards models were used to identify factors that were associated with prolonged hospital length of stay and reduced survival. Culture-positive cases (N = 56) were compared to culture-negative cases (N = 104). Subpopulation analysis of the culture-positive cases compared ceftriaxone-resistant (N = 25) to ceftriaxone-susceptible (N = 31) cases.

Results

We identified 160 cases of SBP (56 culture positive and 104 culture negative; 21 nosocomial, 79 hospital associated, and 60 community acquired). Forty-five percent (N = 25 total, 13 hospital associated and 6 nosocomial) of bacterial isolates were resistant to ceftriaxone, with 37.5% (N = 21) being gram positive, including 8 methicillin-resistant staphylococcus and 6 vancomycin-resistant enterococcus. Multivariate analysis identified hospital-associated SBP, age, alcoholic cirrhosis, and MELD-Na score as variables associated with worse survival (P < 0.05), with a trend toward worse survival in culture-positive cases (P = 0.123). Only MELD-Na was associated with prolonged length of stay.

Conclusions

The burden of resistant pathogens causing SBP is significant, notably in hospital-associated SBP. Culture-positive SBP may represent a higher risk group compared to culture-negative SBP.
Literature
1.
go back to reference Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111:1011–1017.CrossRef Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111:1011–1017.CrossRef
2.
go back to reference Karvellas CJ, Abraldes JG, Arabi YM, et al. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study. Aliment Pharmacol Ther. 2015;41:747.CrossRefPubMed Karvellas CJ, Abraldes JG, Arabi YM, et al. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study. Aliment Pharmacol Ther. 2015;41:747.CrossRefPubMed
4.
go back to reference Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infection. Hepatology. 1985;5:457–462.CrossRefPubMed Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infection. Hepatology. 1985;5:457–462.CrossRefPubMed
5.
go back to reference Franca AV, Giordano HM, Seva-Pereira T, Soares EC. Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. J Gastroenterol. 2002;37:119–122.CrossRefPubMed Franca AV, Giordano HM, Seva-Pereira T, Soares EC. Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. J Gastroenterol. 2002;37:119–122.CrossRefPubMed
6.
go back to reference Rimola A, Almeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674–679.CrossRefPubMed Rimola A, Almeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674–679.CrossRefPubMed
7.
go back to reference McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Surawicz CM, Owen RL, eds. Gastrointestinal and hepatic infections. Philadelphia: WB Saunders; 1995:455. McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Surawicz CM, Owen RL, eds. Gastrointestinal and hepatic infections. Philadelphia: WB Saunders; 1995:455.
8.
go back to reference Blaise M, Paterson D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1994;20:34–38.CrossRefPubMed Blaise M, Paterson D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1994;20:34–38.CrossRefPubMed
9.
go back to reference Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by resistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–1561.CrossRefPubMed Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by resistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–1561.CrossRefPubMed
11.
go back to reference Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, et al. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary center in the United States. J Glob Antimicrob Resist. 2018 May 26; PubMed PMID: 29842975. Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, et al. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary center in the United States. J Glob Antimicrob Resist. 2018 May 26; PubMed PMID: 29842975.
14.
go back to reference Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310–1324.CrossRefPubMed Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310–1324.CrossRefPubMed
15.
go back to reference Chaulk J, Carbonneau M, Qamar H. Third-generation cephalosporin-resistant spontaneous bacterial peritonitis. Can J Gastroenterol Hepatol. 2014;28:83–88.CrossRefPubMedPubMedCentral Chaulk J, Carbonneau M, Qamar H. Third-generation cephalosporin-resistant spontaneous bacterial peritonitis. Can J Gastroenterol Hepatol. 2014;28:83–88.CrossRefPubMedPubMedCentral
16.
go back to reference Piroth L, Pechinot A, Di Martino V, Hansmann Y, Putot A, et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis. 2014 May 23;14:287. PubMed PMID: 24884471; PubMed Central PMCID: PMC4055793. Piroth L, Pechinot A, Di Martino V, Hansmann Y, Putot A, et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis. 2014 May 23;14:287. PubMed PMID: 24884471; PubMed Central PMCID: PMC4055793.
18.
go back to reference Falcone M, Russo A, Pacini G, et al. Spontaneous bacterial peritonitis due to Methicillin-Resistant Staphylococcus Aureus in a patient with cirrhosis: the potential role for daptomycin and review of the literature. Infect Dis Rep. 2015;7:6127.PubMedPubMedCentral Falcone M, Russo A, Pacini G, et al. Spontaneous bacterial peritonitis due to Methicillin-Resistant Staphylococcus Aureus in a patient with cirrhosis: the potential role for daptomycin and review of the literature. Infect Dis Rep. 2015;7:6127.PubMedPubMedCentral
19.
go back to reference Hillebrand DJ, Runyon BA, Yasmineh WG, Rynders GP. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology. 1996;24:1408.CrossRefPubMed Hillebrand DJ, Runyon BA, Yasmineh WG, Rynders GP. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology. 1996;24:1408.CrossRefPubMed
20.
go back to reference Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104.CrossRefPubMed Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104.CrossRefPubMed
21.
go back to reference Pelletier G, Salmon D, Ink O, Hannoun S, Attali P, et al. Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol. 1990;10:327–331. PubMed PMID: 2365982.CrossRefPubMed Pelletier G, Salmon D, Ink O, Hannoun S, Attali P, et al. Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol. 1990;10:327–331. PubMed PMID: 2365982.CrossRefPubMed
22.
go back to reference Bal CK, Bhatia V, Daman R. Predictors of fifty days in-hospital mortality in patients with culture negative neutrocytic ascites. BMC Gastroenterol. 2017 May 16;17:64. PubMed PMID: 28511674; PubMed Central PMCID: PMC5434542. Bal CK, Bhatia V, Daman R. Predictors of fifty days in-hospital mortality in patients with culture negative neutrocytic ascites. BMC Gastroenterol. 2017 May 16;17:64. PubMed PMID: 28511674; PubMed Central PMCID: PMC5434542.
23.
go back to reference Baskol M, Gursoy S, Baskol G, et al. Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients. J clin Gastroenterol. 2003;37:403–405.CrossRefPubMed Baskol M, Gursoy S, Baskol G, et al. Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients. J clin Gastroenterol. 2003;37:403–405.CrossRefPubMed
24.
go back to reference Evans LT, Kim WR, Poterucha JJ, et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology. 2003;37:897–901.CrossRefPubMed Evans LT, Kim WR, Poterucha JJ, et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology. 2003;37:897–901.CrossRefPubMed
Metadata
Title
Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis
Authors
Eric Ardolino
Susan S. Wang
Vilas R. Patwardhan
Publication date
01-08-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05519-4

Other articles of this Issue 8/2019

Digestive Diseases and Sciences 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine